Grafa
Acumen exercises option for JCR technology
Image for illustrative purposes only. Not a real photo.

Acumen exercises option for JCR technology

Share
  • Acumen Pharmaceuticals (NASDAQ:ABOS) exercised its exclusive option to develop and commercialize two Alzheimer’s disease candidates using JCR Pharmaceuticals’ (TSE:4552) J-Brain Cargo platform.
  • The partnership aims to deliver therapeutic antibodies across the blood-brain barrier to better target toxic proteins associated with Alzheimer's disease.
  • JCR Pharmaceuticals is eligible to receive up to US$555 million in milestone payments related to the development and sales of these products.

Acumen Pharmaceuticals (NASDAQ:ABOS) executed its exclusive option to develop and manufacture two Alzheimer's disease treatment candidates using the proprietary blood-brain barrier (BBB)-penetrating platform from JCR Pharmaceuticals (TSE:4552).

This agreement expands upon a partnership initiated in July 2025, which focuses on combining JCR's J-Brain Cargo technology with Acumen’s amyloid beta oligomer-selective antibodies.

JCR Pharmaceuticals is entitled to receive an upfront option payment, followed by potential development milestones of up to US$40 million and sales milestones of up to US$515 million.

The collaboration intends to file an investigational new drug application by mid-2027 to begin formal clinical evaluation of these candidates.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.